<DOC>
	<DOCNO>NCT02254122</DOCNO>
	<brief_summary>Study investigate safety tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) BEA 2180 BR</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Inhalative Doses BEA 2180 BR Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male accord follow criterion ( examine Screening Visit ) : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 1.1 No find deviate normal clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥30 ≤55 year 3 . BMI ≥18.5 BMI &lt; 30 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder 2 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 3 . History relevant orthostatic hypotension , faint spell blackouts 4 . Chronic relevant acute infection 5 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge Investigator 6 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 7 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 8 . Participation another trial investigational drug within two month prior administration trial 9 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 10 . Inability refrain smoke trial 11 . Alcohol abuse ( 60 g/day ) 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior administration trial ) 14 . Excessive physical activity ( within one week prior administration trial ) 15 . Any laboratory value outside reference range indicative underlying disease poor health Exclusion criterion specific study : Asthma chronic obstructive pulmonary disease Glaucoma Urinary tract obstruction Occupational ( professional ) exposure antimuscarinic substance</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>